Preclinical studies in prostate cancer cell lines have demonstrated that downregulating YY1 expression or inhibiting its activity can sensitize tumor cells to the chemotherapy drug cisplatin and enhance its effectiveness [148,149,150]. The gene discussed is YY1; the disease is neoplasm.